Stage 24: Early Dementia Recognition & MCI Intervention
Concept 1 of 4
L24.1

Subjective Cognitive Decline

The earliest signal — what to take seriously, what to reassure.

Warm cream-tinted manuscript page, deep slate margin annotations, slate-blue palette. Subjective cognitive decline — patient-reported cognitive change without objective testing decrement. The earliest signal warranting attention. Margin clusters on what to take seriously.

Subjective cognitive decline (SCD) — patient-reported cognitive change without objective testing decrement — is the earliest cognitive signal warranting clinical attention. Patients with SCD have elevated dementia risk over long follow-up compared to those without; the magnitude is modest but real (HR roughly 2.0-3.0). The clinical response is neither dismissal ("everyone forgets things") nor catastrophizing — it is engaged prevention work with appropriate monitoring.

The clinical recognition. Patient describes worsening memory, attention, processing speed, or general cognitive function relative to their own prior baseline. The change is subjective; objective neuropsychological testing is within normal limits. The patient is typically 50+ years old, sometimes worried about family history, sometimes responding to specific incidents that produced concern. The presentation has elevated frequency in patients with anxiety and depression — psychiatric contributors warrant address.

The workup for SCD. Full medical workup ruling out reversible contributors: thyroid, B12, vitamin D, sleep apnea evaluation if any indication, medication review for cognitive contributors. Mood and anxiety assessment — depression and anxiety frequently produce cognitive complaints that improve with treatment. Cognitive screening (MoCA) to establish current baseline; possibly more detailed neuropsychological testing in selected cases. The workup frequently identifies contributors that resolve the complaints.

The prevention prescription engagement. SCD identifies the patient where the Modifiable Twelve factors (Stage 3) warrant aggressive engagement. Exercise prescription with specificity (Stage 9). Sleep optimization. Social engagement work. Mediterranean-pattern diet. BP and metabolic optimization. Hearing and vision evaluation (Stage 8). Treatment of any mood, anxiety, or sleep disorder identified in workup. The prevention prescription is the substance of clinical response.

Monitoring and follow-up. Annual MoCA or equivalent screening to track trajectory. Reassessment of any contributors over time. Cognitive complaints that persist or progress warrant more detailed evaluation (Stage 24.2 — MCI workup). The patient who engages prevention seriously frequently sees subjective improvement; the patient whose objective performance begins to decline despite engagement warrants further workup. The discipline is to engage SCD seriously — neither dismiss nor over-pathologize — and to use it as the entry point for aggressive prevention work and longitudinal monitoring.

Editorial illustration of SCD risk profile — elevated dementia risk over years of follow-up despite normal current testing, the prodromal frame, the conversion patterns.
The anchor

Subjective cognitive decline (SCD) — patient-reported change without objective testing decrement — has elevated dementia risk (HR ~2-3) over long follow-up. Workup for reversible contributors; engage Modifiable Twelve aggressively; annual MoCA monitoring. The entry point for prevention work.

Painterly editorial illustration of clinical response — when to engage prevention prescription aggressively, what testing and monitoring is appropriate, how to balance reassurance and engagement.
Prove it

A 62-year-old man reports worsening memory over the past year — forgetting names, occasional misplaced items, difficulty with multitasking that wasn't there before. MoCA 28/30. Normal medical workup. PHQ-9 of 7, GAD-7 of 9. How do you respond?

This connects to

Locked concepts unlock as you reach them on the path.

Back